MISHIMA Yuta

Affiliation
Institute of Medicine
Official title
Assistant Professor
ORCID
0000-0003-4945-7346
KAKEN ID
80770263
Office
Cancer Immunotherapy & Immunology
Research keywords
Biomedical engineering
Regulatory Science
Industry-academia collaboration
Tumor immunology
Epigenetics
Regenerative medicine
Research projects
Development and demonstration of a patient tissue-derived 3D tumor-on-a-chip for evaluation of T cell function in cancer immunotherapy2022-04 -- 2025-03MISHIMA YutaJapan Society for the Promotion of Science/Grant-in-Aid for Scientific Research (C)4,030,000Yen
Development of a 3D tumor-on-a-chip platform for cancer immunotherapy2020-04 -- 2021-03TORISAWA Yu-sukeJapan Society of for the Promotion of Science/Grant in Aid for Scientific Research (B)17,810,000Yen
Development of the killing function of iPSC derived CAR-T cell for solid tumor.2020-04 -- 2023-03MISHIMA YutaJapan Society for the Promotion of Science/Grant-in-Aid for Early-Career Scientists4,160,000Yen
Development of patient-derived cancer on-a-chip devices for cancer immunotherapy2017-04 -- 2020-03TORISAWA Yu-sukeJapan Society for the Promotion of Science (JSPS)/Grant in Aid for Scientific Research (B)
ｉＰＳ細胞由来再生Ｔ細胞とがん特異抗原レセプター遺伝子導入による免疫療法の開発2016-04 -- 2019-03MISHIMA YutaJapan Society for the Promotion of Science (JSPS)/Grant-in-Aid for JSPS Fellows5,200,000Yen
Development of a microfluidic device to mimic the function of the thymus for immunotherapy2016-04 -- 2018-03TORISAWA Yu-sukeJapan Society for the Promotion of Science (JSPS)/Grant-in-Aid for Challenging Exploratory Research
がん特異抗原 glypican-3 標的としたiPS細胞由来再⽣T細胞療法の開発2015-06 -- 2016-03京都大学 iPS細胞研究所/iPS 細胞研究所若⼿育成費
転写因⼦の異常で発症する⽩⾎病の新規発症メカニズムについて研究2013-06 -- 2014-05上原記念⽣命科学財団/平成24年度ポストドクトラルフェローシップ
ヒストンアセチル基転移酵素複合体と、その構成因⼦の⾎液細胞における機能研究2009-04 -- 2013-03JST/戦略的創造研究推進事業（CREST）7,296,000Yen
Career history
2021-04 -- (current)University of Tsukuba HospitalOffice for the Promotion of Regenerative MedicineDeputy Director
2020-03 -- (current)University of TsukubaFaculty of MedicineAssistant Professor
2017-04 -- 2020-02Kyoto UniversityCenter for iPS cell Research and Application (CiRA)T-CiRA program, Kaneko Project Sub-PI
2016-04 -- 2019-03Japan society for the promotion of science (JSPS)JSPS Research Fellow
2013-06 -- 2016-06Beth Israel Deaconess Medical Center / Harvard Medical School (BIDMC/HMS)Hematology / OncologyResearch fellow
2015-06 -- 2016-04Kyoto UniversityCenter for iPS research and Application (CiRA)Program specific researcher
2013-04 -- 2013-05千葉大学 医学研究院先端部門高次機能治療学研究講座特任研究員
Degree
2013-03Ph.D. (Medicinal Sciences)Graduate School of Medical and Pharmaceutical Sciences, Chiba University
2009-03M.S. (Pharmacy)Graduate School of Medical and Pharmaceutical Sciences, Chiba University
Licenses and qualifications
2007-05pharmacist
Academic societies
2021-03 -- (current)The Japanese Cancer Association
2013-03 -- (current)International Society of Stem Cell Research (ISSCR)
2014-02 -- (current)THE JAPANESE SOCIETY FOR REGENERATIVE MEDICINE
Honors & Awards
2013-06Uehara postdoctoral fellowship
2013-03医学薬学府長賞（首席）
2012-12Annual Best Research Award
2012-09第1回 Microsoft Kinnect for Windows Contest 技術賞
2012-03優秀発表賞（第13回 Pharmaco-hematology シンポジウム）
2012-03学生優秀発表賞（日本薬学会 132年会）
2011-12第4回テクノルネサンスアイデアコンテスト最優秀賞
2011-07学術奨励賞（第71回 日本血液学会学術集会）
Articles
Books
  • 【特集】iPSの社会的意義「iPS細胞の応⽤研究 −これまでの応⽤例と課題、最新の応⽤例」
    三嶋雄太 金子新
    『⽣物の科学 遺伝』/株式会社エヌ・ティー・エス, 2017-09
Conference, etc.
  • 【CancerX 研究開発治療】～10年後のがん治療はどうなる？～
    上野直人; 工藤千恵; 櫻井 英幸; 村垣善浩; 三嶋雄太
    World Cancer Week 2021/2021-1-31--2021-2-6
  • Hbo1-Brd1 複合体による H3K14 のアセチル化は胎仔期の⾚⾎球造⾎に重要である
    三嶋雄太
    ⽇本薬学会 第132年会/2012-03-01
  • Hbo1-Brd1 複合体によるヒストン H3K14 アセチル化を介した胎仔期⾚⾎球造⾎機構の解析
    三嶋雄太
    第13回 Pharmaco-Hematology シンポジウム/2012-06-01
  • iPS細胞研究と再⽣医療ビジネス最前線
    三嶋雄太
    ボストン⽇本⼈研究者交流会（BJRF）第 139 回講演会/2015-10-17
  • 留学帰国後のキャリアパス：学振 PD、科研費獲得と共同研究の経験から
    三嶋雄太
    第91 回 ⽇本⽣化学会⼤会/2018-09-24
  • CancerX 先端医療
    三嶋雄太
    CancerX Summit 2019/2019-02-03
  • がんと再⽣医療
    三嶋雄太
    つくば再⽣医療・細胞治療カンファレンス講演会/2019-03-29
  • iPS細胞が作り出す社会とビジネス
    三嶋雄太
    関⻄⼤学 商学部新⼊⽣歓迎特別⾏事講演/2019-04-02
  • The Hbo1-Brd1/Brpf2 complex is responsible for global acetylation of histone H3 at lysine 14 and required for fetal liver erythropoiesis
    Yuta Mishima
    52nd ASH Annual Meeting and Exposition/2010-12-01
  • Histone Acetylation Mediated by Brd1 Is Crucial for Cd8 Gene Activation during Early Thymocyte Development.
    Yuta Mishima
    56nd ASH Annual Meeting and Exposition/2014-12-01
  • Microfluidic Tissue Engineering of Perfusable 3D Vascular Networks on a Chip using Human iPS cells.
    Mishima Yuta
    ISSCR 2017 Annual Meeting/2017-06-01
  • Microfluidic Tissue Engineering of a 3D Vascularized Tissue-on-a-Chip using Human iPSC-derived Cells to Study Cancer Immunotherapy
    Y Torisawa; Y Mishima; E Sano; M Waseda; H Takakubo; C M...
    5th Tissue Engineering and Regenerative Medicine International Society World Congress (TERMIS-WC2018)/2018-09-01
  • Engineering of a 3D Vascularized Tissue-on-a-Chip using Human iPSC-derived Cells
    Y Torisawa; Y Mishima; E Sano; H Takakubo; C Mori; S Kaneko
    22nd International Conference on Miniaturized Systems for Chemistry and Life Sciences (µTAS 2018)/2018-11-01
  • Engineering of Perfusable 3D Vascularized Tumor-on-a-Chip Using hiPSC-derived Endothelial cells
    三嶋雄太
    The 18th Congress of the Japanese society for regenerative medicine/2019-03-01
  • Modeling cancer immunotherapy in a perfusable 3D vascularized tumor-on-a-Chip using universal iPSC-derived endothelial cells.
    Yuta Mishima; Masazumi Waseda; Hitomi Takakubo; Wang Bo; ...
    CiRA 2019 International Symposium/2019-11-28
  • MODELING CANCER IMMUNOTHERAPY IN A PERFUSABLE 3D VASCULARIZED TUMOR-ON-A-CHIP USING HLA-KO UNIVERSAL HUMAN IPSC-DERIVED ENDOTHELIAL CELLS
    Yuta Mishima Masazumi Waseda Hitomi Takakubo Chihiro M...
    ISSCR 2020 Virtual/2020-06-26
Intellectural property rights
  • ⽪膚⽤粘着シート
    三嶋雄太 花角尚子 小日向恭祐 岡和樹 閔弘圭 藤井知
  • Hematopoietic progenitor cell marker
    金子新 入口翔一 三嶋雄太 葛⻄義明 林哲 有馬寿来留
Talks
  • 【CnacerX 研究開発治療】～10年後のがん治療はどうなる？～
    上野直人; 工藤千恵; 櫻井 英幸; 村垣善浩; 三嶋雄太
    World Cancer Week 2021/2021-1-31--2021-02-06
  • Rejuvenated iPS-T Cells for the application of Antigen-Specific Immunotherapy
    三嶋雄太
    京都⼤学⼤学院教育コース「再⽣医療・臓器再建医学コース」83rd ミーティング（英語授業）/2016-02-12
  • iPS細胞とレギュラトリーサイエンス
    三嶋雄太
    順天堂⼤学医学部 医療の経済学 第10回講義/2019-06-17
Professional activities
2017-04 -- 2020-03バイオインダストリー協会バイオサイエンスとインダストリー編集委員会 再生医療トピックス委員
University Management
2021-04 -- (current)Office for the Promotion of Regenerative Medicine, University of Tsukuba HospitalDeputy Director
Other activities
2018-01 -- (current)

(Last updated: 2024-11-14)